Last reviewed · How we verify

Sofosbuvir/Ledipasvir 12W — Competitive Intelligence Brief

Sofosbuvir/Ledipasvir 12W (Sofosbuvir/Ledipasvir 12W) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NS5A inhibitor and NS5B polymerase inhibitor. Area: Infectious Disease.

phase 3 NS5A inhibitor and NS5B polymerase inhibitor NS5A protein and NS5B polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Sofosbuvir/Ledipasvir 12W (Sofosbuvir/Ledipasvir 12W) — Iran Hepatitis Network. Sofosbuvir/Ledipasvir 12W is a combination of a nucleotide analog inhibitor of the hepatitis C virus NS5B polymerase and a potent inhibitor of the hepatitis C virus NS5A protein.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sofosbuvir/Ledipasvir 12W TARGET Sofosbuvir/Ledipasvir 12W Iran Hepatitis Network phase 3 NS5A inhibitor and NS5B polymerase inhibitor NS5A protein and NS5B polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NS5A inhibitor and NS5B polymerase inhibitor class)

  1. Iran Hepatitis Network · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sofosbuvir/Ledipasvir 12W — Competitive Intelligence Brief. https://druglandscape.com/ci/sofosbuvir-ledipasvir-12w. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: